Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Yuen

Psychiatry Honolulu, HI Medical Doctor

NPI 1871654640 CMS profile 388043

1188 Bishop St, Ste 806, Honolulu, HI 96813

Open in the dashboard

General payments

$6,295

314 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Yuen of Honolulu, HI is reported in the CMS Open Payments database as having received $6,295 across 314 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $286 7
2024 General $777 31
2023 General $1,457 65
2022 General $1,024 55
2021 General $1,114 56
2020 General $972 51
2019 General $666 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Yuen
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Gregory Yuen were reported at $286. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Gregory Yuen Psychiatry median Middle half National median
2019 $666 $184 $59–$605 $163
2020 $972 $119 $36–$372 $114
2021 $1,114 $143 $43–$576 $132
2022 $1,024 $153 $50–$590 $149
2023 $1,457 $170 $56–$651 $160
2024 $777 $179 $57–$673 $164
2025 $286 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,214 72 payments
  2. Sunovion Pharmaceuticals Inc. $871 46 payments
  3. Neurocrine Biosciences, Inc. $737 24 payments
  4. Otsuka America Pharmaceutical, Inc. $601 28 payments
  5. Alkermes, Inc. $564 28 payments
  6. Lundbeck LLC $518 29 payments
  7. ITI, Inc. $402 16 payments
  8. AbbVie, Inc. $382 21 payments
  9. Teva Pharmaceuticals USA, Inc. $373 17 payments
  10. Allergan Inc. $296 20 payments
  11. Other $337 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,239 312 payments
  2. Education $56 2 payments
Products named General payments · program years 2019–2025
  1. TRINTELLIX $1,035 58 payments
  2. LATUDA $871 46 payments
  3. LYBALVI $547 27 payments
  4. INGREZZA $510 12 payments
  5. ARISTADA Cns $483 27 payments
  6. ARISTADA Cns $483 27 payments
  7. CAPLYTA $402 16 payments
  8. VRAYLAR $382 21 payments
  9. REXULTI $344 19 payments
  10. ARISTADA Cns $320 18 payments
  11. Other $3,113 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

636

Median for Psychiatry & Neurology: 100

Drug cost

$34,514

Median for Psychiatry & Neurology: $2,986

Branded share of claims

16.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 27 $8,640
Aripiprazole Generic 48 $4,237
Quetiapine Fumarate Generic 83 $3,334
Clozapine Generic 50 $2,558
Divalproex Sodium Er Divalproex Sodium Brand 29 $2,328
Ziprasidone Hcl Generic 43 $2,271
Venlafaxine Hcl Er Venlafaxine Hcl Brand 54 $2,118
Olanzapine Generic 49 $1,817
Fluoxetine Hcl Generic 25 $1,695
Bupropion Xl Bupropion Hcl Brand 24 $890

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $194
$194 — —
VRAYLAR
  • AbbVie, Inc. $137
$137 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $98
$98 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $68
$68 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

314 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record